Interactions between recreational drugs and antiretroviral agents.
about
Toxicity of amphetamines: an updateAntiretroviral medication: an emerging category of prescription drug misuseFunctional impact of ABCB1 variants on interactions between P-glycoprotein and methadoneThe role of lopinavir/ritonavir (Kaletra) in the management of HIV infected adults.Performance of the Tobacco, Alcohol, Prescription Medication, and Other Substance Use (TAPS) Tool for Substance Use Screening in Primary Care PatientsAbsorption, distribution, metabolism and excretion pharmacogenomics of drugs of abuse.Buffering effects of general and medication-specific social support on the association between substance use and HIV medication adherencePharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Non-injection drug use and HIV disease progression in the era of combination antiretroviral therapy.The Expanding Class of Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of HIV-1 InfectionSynergistic effects of food insecurity and drug use on medication adherence among people living with HIV infection.A Brief Patient Self-administered Substance Use Screening Tool for Primary Care: Two-site Validation Study of the Substance Use Brief Screen (SUBS)Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.Drug interactions in the management of HIV infection.Pharmacotherapy, vaccines and malaria advice for HIV-infected travellers.Party drugs: properties, prevalence, patterns, and problems.Validation of Self-Administered Single-Item Screening Questions (SISQs) for Unhealthy Alcohol and Drug Use in Primary Care Patients.Practical perspectives on the use of tipranavir in combination with other medications: lessons learned from pharmacokinetic studies.Club drugs and HIV infection: a review.Aging and HIV infectionA review of nelfinavir for the treatment of HIV infection.Pharmacokinetic interactions between buprenorphine and antiretroviral medications.The next therapeutic challenge in HIV: polypharmacy.Biomedical approaches to HIV preventionImplications of efavirenz for neuropsychiatry: a review.Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients.GHB and synthetic cathinones: clinical effects and potential consequences.Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolismAntiretroviral therapy in HIV-infected adolescents: clinical and pharmacologic challenges.Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2).A review of drug-drug interactions in older HIV-infected patients.Prospective, open-label comparative study of liver toxicity in an unselected population of HIV-infected patients treated for the first time with efavirenz or nevirapine.Frequency and severity of potential drug interactions in a cohort of HIV-infected patients Identified through a Multidisciplinary team.
P2860
Q22252794-7441EC11-8066-4FB5-8D4C-A00E8957AEB4Q26852974-4883BEB2-9548-42BF-A36C-12B550494178Q28488223-9C42AFBD-E2A8-4EF2-8459-CAC4DE298834Q30343901-863B659E-56A6-4E0D-B239-061D7177F56FQ30837457-C579D5A6-0AED-4469-8DCA-BC5A47482BD6Q34165511-8BF3B1E7-4045-4A87-A2C9-1C82DC2DE8CAQ34624889-0A2D86E8-4B48-4D7A-909D-B3CCC869D831Q34745586-4EA1BCB6-A3AF-4AC9-B010-855C5DE80D65Q34851665-F234DE1F-6F1E-4A19-910A-28A96056F7E5Q35111300-F683AFE9-2CE8-481A-ADF6-050486E8ECA7Q35587302-BE03F833-B9EB-4490-940F-926B20475E24Q35762993-CB893E38-C275-404F-8A3A-C94F15D95CA3Q35898538-92641B93-2838-4AD4-9A0A-68D4064AAA70Q36066083-9106D6DD-EC03-428B-8BD0-67600C0BBA6AQ36161252-CFE1316C-6784-4EF5-8D00-1D2F4A92D8F6Q36209983-E351498B-D1A2-41B4-8FCC-83472EF5A647Q36258417-0567D1C9-8A44-4CD3-BB67-7DA497F672CDQ36375914-43D1DBC3-1AB7-4F43-81DD-7EDC69E84E98Q36451059-3DA1A870-118F-4D00-B83A-21992B4CC86CQ36482458-39F12C95-2224-480B-A8D2-697275ACB2D3Q36546278-5CBA8013-2EC1-47C9-A991-B4B2920D84CEQ36655057-D03B7595-B85B-4FA8-9BB4-F5D395FF3985Q37025385-2B060C6C-C2BD-40F4-891A-1FC8C351914DQ37386665-C63AD20C-3FC3-4F57-95C0-9BF1081B7BACQ37801927-A2A71777-7197-49E7-BDD1-CB1B973777E0Q37845854-C5196848-2B32-4BED-851E-09A21DB2648AQ37940942-39BBDC76-4C28-46F2-88B2-60F02EAC5701Q38852149-FFC0B517-5392-4898-9F4B-DC57BEECE61EQ38910835-A6DB2E00-03AF-47DA-A308-0C752B49B4BEQ39779618-5FD9EC71-A65C-4964-916E-EBCEDF6F6179Q41996857-A1C38CF3-7920-4E8B-A8EA-F8B1EB3E57E8Q46923095-0A04ED59-8E61-44C9-9D7F-8AAC25500C1EQ47407447-BF9061DF-08BA-48D0-8549-CC84F746F808
P2860
Interactions between recreational drugs and antiretroviral agents.
description
2002 nî lūn-bûn
@nan
2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Interactions between recreational drugs and antiretroviral agents.
@ast
Interactions between recreational drugs and antiretroviral agents.
@en
Interactions between recreational drugs and antiretroviral agents.
@nl
type
label
Interactions between recreational drugs and antiretroviral agents.
@ast
Interactions between recreational drugs and antiretroviral agents.
@en
Interactions between recreational drugs and antiretroviral agents.
@nl
prefLabel
Interactions between recreational drugs and antiretroviral agents.
@ast
Interactions between recreational drugs and antiretroviral agents.
@en
Interactions between recreational drugs and antiretroviral agents.
@nl
P2860
P356
P1476
Interactions between recreational drugs and antiretroviral agents.
@en
P2093
Alice Lin-In Tseng
Tony Antoniou
P2860
P304
P356
10.1345/APH.1A447
P407
P577
2002-10-01T00:00:00Z